Stock Price, News, Quote and Profile of THERAPEUTICSMD INC(NASDAQ:TXMD) stock

THERAPEUTICSMD INC

NASDAQ:TXMD (1/8/2025, 2:23:53 PM)

1.09

-0.05 (-4.39%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryPharmaceuticals

GICS SubIndustryPharmaceuticals

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%84.14%

Sales Q2Q%1194%

CRS5.46

6 Month-38.38%

Overview

Earnings (Last)11-11 2024-11-11/amc

Earnings (Next)N/A N/A

Ins Owners1.77%

Inst Owners29.64%

Market Cap12.57M

Shares11.53M

PEN/A

Fwd PE3.05

Dividend YieldN/A

Analysts43.33

Short Float %0.19%

Short Ratio0.98

IPO01-31 2001-01-31

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 1 full-time employees. The company went IPO on 2001-01-31. The company receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).